ArticleInternational journal of clinical oncology2026
Longitudinal assessment of health-related quality of life, sleep quality, and gustation in patients with advanced urothelial carcinoma receiving late-line enfortumab vedotin monotherapy.
Article in International journal of clinical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
backgroundTo describe real-world data on health-related quality of life (HRQoL) in patients with locally advanced or metastatic urothelial carcinoma receiving late-line enfortumab vedotin (EV) monotherapy.
methodsThis study included 19 previously treated locally advanced or metastatic urothelial carcinoma patients who received late-line EV monotherapy. Time-course changes in the domains and subscales of the EORTC QLQ-C30, Functional Assessment of Cancer Therapy-General, multi-item short form-8, Pittsburgh Sleep Quality Index (PSQI), and chemotherapy-induced taste alteration scale (CiTAS) questionnaires during EV monotherapy up to 10 cycles were evaluated using linear mixed effects models for repeated measures.
resultsGenerally, a negative effect on physical function-related domains was observed during EV monotherapy. In the analysis of the EORTC-QLQ-C30 global health status/QoL subscale, three (16%), nine (47%), and seven (37%) patients experienced clinically meaningful improvement, stability, and clinically meaningful deterioration during EV monotherapy, respectively, and Kaplan-Meier estimation demonstrated that the median number of cycles to deterioration was six. The global PSQI score showed marginally normalized sleep quality, with gradual decrease in population of patients with poor sleep quality (global PSQI score, ≥ 6). After the initiation of EV monotherapy, dysgeusia with worsening subscales in the decline in basic taste and general taste alterations occurred early in the first to fourth cycles. In contrast, the appetite loss score on the EORTC QLQ-C30 questionnaire did not change during EV monotherapy.
conclusionLate-line EV monotherapy showed a generally acceptable negative impact on HRQoL. Effective interventions are needed to maintain physical functioning and gustatory abilities in patients receiving EV monotherapy.
Indexed as
Identifiers
41457130What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.